Eli Lilly Plans Insulin Manufacturing Investments - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eli Lilly Plans Insulin Manufacturing Investments


Eli Lilly plans to invest more than $700 million to enhance its global insulin-manufacturing capacity in Puerto Rico, France, and China as well as in Indianapolis, Indiana, the site of the company's global headquarters. The new investment increases Eli Lilly's manufacturing commitment in the past year to more than $1 billion in planned investments for insulin.

Nearly half of the $1-billion investment will improve the company's Indianapolis sites, where Eli Lilly has been manufacturing insulin since it introduced the first commercially available insulin product in 1923. The new manufacturing investments will support existing and future insulin-based medicines. In France, the company is investing $120 million to enhance insulin-cartridge manufacturing capacity. At its sites in Indianapolis and Puerto Rico, the company is investing $245 million to expand insulin active- ingredient and delivery-device manufacturing capacity. In addition, the company will invest $350 million to expand insulin-cartridge manufacturing capacity in China.

In addition to these new investments, Eli Lilly recently reported other insulin-related commitments in Indianapolis totaling $320 million to expand insulin active-ingredient and drug-product manufacturing capacity as well as an additional $80 million in ancillary projects. Together, this brings the company's total investment commitment during the past year to more than $1 billion, which will be invested during the next several years.

The commitment to expand insulin production in China is the latest in a series of diabetes-related investments, such as the opening of the Lilly China Research and Development Center in Shanghai last year. The company is also investing in diabetes research. The company currently has 14 new molecular entities in clinical development, including three under regulatory review and another in Phase III, for the treatment of diabetes and related complications.

Source: Eli Lilly

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here